AU Patent

AU2021398051A1 — Crystal form of tolebrutinib, preparation method therefor and use thereof

Assigned to Principia Biopharma Inc · Expires 2023-07-27 · 3y expired

What this patent protects

Provided are a crystal form of Tolebrutinib (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a BTK inhibitor drug and a drug for treati…

USPTO Abstract

Provided are a crystal form of Tolebrutinib (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a BTK inhibitor drug and a drug for treating multiple sclerosis. The crystal form of Tolebrutinib has one or more improved properties compared with the prior art, and is of great value to the optimization and development of the drug in the future.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021398051A1
Jurisdiction
AU
Classification
—
Expires
2023-07-27
Drug substance claim
No
Drug product claim
No
Assignee
Principia Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.